Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2008Expert Opinion on Emerging Drugs

Emerging drugs for hepatitis C

View Full Paper
Ask AI
Bookmark
Share

Authors

VSVincent SorianoUniversidade Federal de Minas GeraisAMAntonio MadejónUniversitat de Miguel Hernández d'ElxEVEugenia VispoJohnson & Johnson (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Soriano et al. (2008) studied this question.

synapsesocial.com/papers/6aa6110bd3d41ccc68922a86https://doi.org/10.1517/14728214.13.1.1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV–HIV International Panel2007 · 350 citations
  2. 2Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line1999 · 2,815 citations
  3. 3VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells2006 · 200 citations